BIOGEN for BIOGEN
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill. Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
Pharmacy PHA
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
| DANIEL HARDER | — |
Manufacturing MAN
General issues related to the manufacturing workforce
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| DANIEL HARDER | — |
Trade (domestic/foreign) TRD
Trade-related public policy around tariffs and intellectual property, no related bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| DANIEL HARDER | — |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| DANIEL HARDER | — |
Copyright/Patent/Trademark CPT
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER | — |
Health Issues HCR
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| JOHN RAYMOND GIBSON | — |
| TYLER HANSON | — |
| DANIEL HARDER | — |
| MATTHEW ITZKOWITZ New | — |
| ALI LAKHANI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.